# Colorectal Analysis for Signature Cancer Assessment Using Delta-HLD

> **NCT07148297** · — · RECRUITING · sponsor: **Epiliquid Holding, Inc** · enrollment: 600 (estimated)

## Conditions studied

- Colo-rectal Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07148297
- **Lead sponsor:** Epiliquid Holding, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-30
- **Primary completion:** 2025-08
- **Final completion:** 2026-12
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07148297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07148297, "Colorectal Analysis for Signature Cancer Assessment Using Delta-HLD". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT07148297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*